This multicenter observational study will evaluate the use of RoActemra/Actemra (tocilizumab) in monotherapy in patients with active moderate to severe rheumatoid arthritis unable to use methotrexate. Eligible patients initiated on RoActemra/Actemra treatment will be followed for 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01669902?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
